Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ITOS iTeos Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ITOS
Price (delayed)
$6.7
Market cap
$256.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.06
Enterprise value
$104.64M
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of
Highlights
The EPS is up by 19% year-on-year and by 8% since the previous quarter
iTeos Therapeutics's debt has decreased by 13% YoY
ITOS's equity is down by 4.6% from the previous quarter but it is up by 4.1% YoY
Key stats
What are the main financial stats of ITOS
Market
Valuations
Earnings
Shares outstanding
38.27M
Market cap
$256.43M
Enterprise value
$104.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
8.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.99
Revenue
$35M
Gross profit
$35M
Operating income
-$152.32M
Net income
-$130.81M
EBIT
-$117.85M
EBITDA
-$116.59M
Free cash flow
-$100.33M
Per share
Balance sheet
Liquidity
EPS
-$3.06
EPS diluted
-$3.06
Free cash flow per share
-$2.32
Book value per share
$14.75
Revenue per share
$0.81
TBVPS
$15.24
Total assets
$658.87M
Total liabilities
$95.45M
Debt
$5.05M
Equity
$563.42M
Working capital
$499.05M
Debt to equity
0.01
Current ratio
14.13
Quick ratio
13.71
Net debt/EBITDA
1.3
Margins
Efficiency
Dividend
EBITDA margin
-333.1%
Gross margin
100%
Net margin
-373.7%
Operating margin
-435.2%
Return on assets
-18.5%
Return on equity
-21.4%
Return on invested capital
-23.4%
Return on capital employed
-19%
Return on sales
-336.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITOS stock price
How has the iTeos Therapeutics stock price performed over time
Intraday
4.04%
1 week
-10.67%
1 month
32.94%
1 year
-45.08%
YTD
-12.76%
QTD
12.23%
Financial performance
How have iTeos Therapeutics's revenue and profit performed over time
Revenue
$35M
Gross profit
$35M
Operating income
-$152.32M
Net income
-$130.81M
Gross margin
100%
Net margin
-373.7%
The operating income rose by 12% YoY and by 4.5% QoQ
The operating margin has increased by 4.5% from the previous quarter
iTeos Therapeutics's net margin has increased by 2.7% QoQ
The company's net income rose by 3.3% YoY and by 2.7% QoQ
Price vs fundamentals
How does ITOS's price correlate with its fundamentals
Growth
What is iTeos Therapeutics's growth rate over time
Valuation
What is iTeos Therapeutics stock price valuation
P/E
N/A
P/B
0.45
P/S
8.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.99
The EPS is up by 19% year-on-year and by 8% since the previous quarter
ITOS's P/B is 72% below its 5-year quarterly average of 1.6 and 25% below its last 4 quarters average of 0.6
ITOS's equity is down by 4.6% from the previous quarter but it is up by 4.1% YoY
The P/S is 27% lower than the last 4 quarters average of 11.4
Efficiency
How efficient is iTeos Therapeutics business performance
The ROIC is up by 22% year-on-year and by 2.9% since the previous quarter
The ROA has increased by 8% YoY and by 4.1% from the previous quarter
The ROE has grown by 7% YoY and by 3.6% from the previous quarter
The return on sales is up by 2.1% since the previous quarter
Dividends
What is ITOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITOS.
Financial health
How did iTeos Therapeutics financials performed over time
The current ratio is up by 12% since the previous quarter and by 4.6% year-on-year
The quick ratio is up by 12% QoQ and by 8% YoY
iTeos Therapeutics's debt is 99% lower than its equity
iTeos Therapeutics's debt has decreased by 13% YoY
ITOS's equity is down by 4.6% from the previous quarter but it is up by 4.1% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.